CymaBay Therapeutics (CBAY) Announces Oral Late-Breaking Presentation of Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With PBC at AASLD
Go back to CymaBay Therapeutics (CBAY) Announces Oral Late-Breaking Presentation of Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With PBC at AASLDCAL-BAY INTL (NASDAQ: CBAY) | Delayed: 32.48 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $32.48 | 52 Week High | $3.04 | |||
Open | $32.48 | 52 Week Low | $0.82 | |||
Day High | $32.48 | P/E | N/A | |||
Day Low | $32.48 | EPS | $0.00 | |||
Volume | 27,030 |